Nadorameran

Drug Profile

Nadorameran

Alternative Names: CV-7201; CV-7201-mRNA; CV-7201-RNActive; RNActive® rabies vaccines - CureVac

Latest Information Update: 17 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rabies

Most Recent Events

  • 10 Jan 2018 CureVac plans a phase I trial for Rabies (Prevention) in 2018
  • 11 Jan 2017 Interim efficacy data from the first-in-human phase I trial in Rabies (In volunteers, Prevention) released by CureVac
  • 11 May 2016 Phase I development is ongoing in Germany (Intradermal, needle-free injection & needle-based injection and IM, needle-based injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top